Clinical trials: Acute Urinary Retention
Prostate Hyperplasia
FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)
To establish whether the administration of FLOMAX® improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention and to determine whether spontaneous voiding is maintained over the course of…
- Trial name
- NCT02244294
- Testing
- FLOMAX® capsules
- Volunteers
- 176 people
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
Adherence and length of treatment with a 5-alpha reductase inhibitor (5ARI) therapy may be associated with improved clinical outcomes for patients with enlarged prostates (EP) and lower health care related costs.
- Trial name
- NCT01376258
- Testing
- 5ARI
- Volunteers
- 28,903 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia
This retrospective study aims to quantify the relationship between 5-alpha-reductase inhibitor (5ARI) adherence / length of therapy and the likelihood of acute urinary retention (AUR) or prostate surgery in patients with benign…
- Trial name
- NCT01334723
- Testing
- Adherent with 5-alpha-reductase inhibitor (5ARI) therapy, Non-adherent to 5ARI therapy
- Volunteers
- 35,032 people
- Sponsor
- GlaxoSmithKline
BPH
Study to Assess the Efficacy, Safety and Tolerability of (iTind)
Subjects with AUR secondary to BPO that comply with Inclusion/Exclusion Criteria. A total of 50 eligible subjects will be recruited into the study to receive treatment with iTind system.
- Trial name
- NCT03239951
- Testing
- iTind
- Where
- 3 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Medi-Tate Ltd.
Prostatic Hyperplasia, Acute Urinary Retention
ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH
To assess the efficacy of alfuzosin 10mg OD in the management of acute urinary retention associated with BPH. To assess the safety of alfuzosin in this population and health care consumption.
- Trial name
- NCT00290030
- Testing
- Alfuzosin
- Volunteers
- 800 people
- Sponsor
- Sanofi
Prostatic Hyperplasia
Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database
Adherence and length of therapy with 5-alpha reductase inhibitor (5ARI) treatment may be associated with improved clinical outcomes of enlarged prostate (EP) as well as lower health care costs.
- Trial name
- NCT01381510
- Testing
- 5-alpha Reductase Inhibitor (5ARI)
- Volunteers
- 54,459 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
This retrospective study aims to assess the clinical and economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI monotherapy or combination therapy…
- Trial name
- NCT01386983
- Testing
- 5ARI, 5ARI + AB
- Volunteers
- 332 people
- Sponsor
- GlaxoSmithKline
Urinary Retention, Catheter-Associated Urinary Tract Infection
Effectiveness and Cost-effectiveness of the T-Control® Catheter in Patients With Acute Urine Retention
The general purpose of this study is to assess the preliminary effectiveness and cost-effectiveness of the T-Control® catheter versus the Foley type catheter in patients with Acute Urine Retention.
- Conditions
- Urinary Retention, Catheter-Associated Urinary Tract Infection, Catheter Complications
- Trial name
- NCT05643950
- Testing
- Foley catheter, T-Control catheter
- Where
- 2 sites in Spain
- Sponsor
- Rethink Medical SL
Acute Urinary Retention
Alfuzosin for Treating Acute Urinary Retention
The primary objective of the study is to assess the efficacy of alfuzosin 10mg daily in the return to successful voiding after removal of the catheter following a first episode of acute urinary retention (AUR) in patients…
- Trial name
- NCT00336921
- Testing
- Alfuzosin
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sanofi
Acute Urinary Retention, Benign Prostate Hypertrophy(BPH)
Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention
This randomized, double-blind, placebo-controlled Phase 2 study is evaluating Teverelix DP in men following a first episode of acute urinary retention (AUR) associated with benign prostatic hyperplasia (BPH), a population at risk…
- Trial name
- NCT07733934
- Testing
- Teverelix DP
- Volunteers
- 126 people
- Sponsor
- Antev Ltd.
Acute Urinary Retention, Benign Prostatic Hyperplasia
Prostatic Urethral Lift in Subject With Acute Urinary Retention
Assess feasibility and safety of the Prostatic Urethra Lift (PUL) procedure in patients with acute urinary retention secondary to benign prostatic hyperplasia (BPH).
- Trial name
- NCT03194737
- Testing
- UroLift System Procedure
- Where
- 6 sites in United Kingdom
- Volunteers
- 101 people
- Sponsor
- NeoTract, Inc.
Prostatic Hyperplasia
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
This retrospective study aims to assess the impact of early vs delayed 5-alpha-reductase inhibitor (5ARI) therapy in patients with BPH on alpha-blocker (AB) therapy and the risk of acute urinary retention (AUR), prostate-related…
- Trial name
- NCT01332487
- Testing
- 5ARI + AB
- Volunteers
- 4,068 people
- Sponsor
- GlaxoSmithKline
Urinary Retention, Prostatic Hyperplasia
Clinical Trial in Males With BPH (Enlarged Prostate)
A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH. Free study-related medical care provided.
- Conditions
- Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Trial name
- NCT00029822
- Testing
- Alfuzosin (SL770499)
- Where
- 54 sites in United States, Australia and 15 more
- Volunteers
- 1,522 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
In patients with benign prostatic hyperplasia (BPH), combination therapy with an alpha-blocker (AB) and a 5 alpha-reductase inhibitor (5ARI) has been shown to reduce the progression of acute urinary retention (AUR) and the…
- Trial name
- NCT01435954
- Testing
- Early combination therapy, Delayed combination therapy
- Volunteers
- 13,551 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter
The purpose of this study is to evaluate the efficacy and safety of dutasteride at reducing relapse rates of Acute Urinary Retention (AUR), including reduction in surgical intervention for benign prostatic hyperplasia (BPH), in…
- Trial name
- NCT00421421
- Testing
- Dutasteride
- Where
- 25 sites in United Kingdom
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline
Urinary Retention
Alfuzosin Versus Placebo in Acute Urinary Retention
The primary objective of the study is to investigate if 14 days of treatment with Alfuzosin compared to placebo, will increase the number of patients with satisfying spontaneous voiding after acute urinary retention treated with…
- Trial name
- ALF-RIK (NCT00453908)
- Testing
- Alfuzosin
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Sanofi